An update on radiation therapy in head and neck cancers

References

• Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18(9):1221–1237.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965.
   PubMed Web of Science ®Google Scholar
• Grégoire V, Langendijk JA, Nuyts S. Advances in radiotherapy for head and neck cancer. J Clin Oncol. 2015;33(29):3277–3284.
   PubMed Web of Science ®Google Scholar
• Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12(2):127–136.
   PubMed Web of Science ®Google Scholar
• Hawkins PG, Lee JY, Mao Y, et al. Sparing all salivary glands with IMRT for head and neck cancer: longitudinal study of patient-reported xerostomia and head-and-neck quality of life. Radiother Oncol. 2018;126(1):68-74.
   Web of Science ®Google Scholar
• Mazzola R, Ferrera G, Alongi F, et al. Organ sparing and clinical outcome with step-and-shoot IMRT for head and neck cancer: a mono-institutional experience. Radiol Med. 2015;120(8):753–758.
   PubMed Web of Science ®Google Scholar
• Ursino S, D’Angelo E, Mazzola R, et al. A comparison of swallowing dysfunction after three-dimensional conformal and intensity-modulated radiotherapy: a systematic review by the Italian Head and Neck Radiotherapy Study Group. Strahlenther Onkol. 2017;193(11):877–889.
   PubMed Web of Science ®Google Scholar
• Mazzola R, Ricchetti F, Fersino S, et al. Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment: a dose-volume analysis. Head Neck. 2016;38(Suppl 1):E815–E819.
   PubMedGoogle Scholar
• Feng M, Jabbari S, Lin A, et al. Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer. Radiother Oncol. 2005;77(1):32–38.
   PubMed Web of Science ®Google Scholar
• Yoo J, Henderson S, Walker-Dilks C, et al. Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer. Clin Oncol (R Coll Radiol). 2013;25(4):e33–e66.
   PubMed Web of Science ®Google Scholar
• Pohar S, Brown R, Newman N, et al. What does PET imaging add to conventional staging of head and neck cancer patients? Int J Radiat Oncol Biol Phys. 2007;68:383–387.
   PubMed Web of Science ®Google Scholar
• Mazzola R, Alongi P, Ricchetti F, et al. 18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes. Radiol Med. 2017;122(12):952–959.
   PubMed Web of Science ®Google Scholar
• Thiagarajan A, Caria N, Schoder H, et al. Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination. Int J Radiat Oncol Biol Phys. 2012;83:220–227.
   PubMed Web of Science ®Google Scholar
• Riegel AC, Berson AM, Destian S, et al. Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET/CT fusion. Int J Radiat Oncol Biol Phys. 2006;65:726–732.
   PubMed Web of Science ®Google Scholar
• Silvoniemi A, Suilamo S, Laitinen T, et al. Repeatability of tumour hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer. Eur J Nucl Med Mol Imaging. 2017 Oct 26. DOI:10.1007/s00259-017-3857-3
   PubMed Web of Science ®Google Scholar
• Rasmussen JH, Nørgaard M, Hansen AE, et al. Feasibility of multiparametric imaging with PET/MR in head and neck squamous cell carcinoma. J Nucl Med. 2017;58(1):69–74.
   PubMed Web of Science ®Google Scholar
• Houweling AC, Wolf AL, Vogel WV, et al. FDG-PET and diffusion-weighted MRI in head-and-neck cancer patients: implications for dose painting. Radiother Oncol. 2013;106(2):250–254.
   PubMed Web of Science ®Google Scholar
• Wong KH, Panek R, Welsh L, et al. The predictive value of early assessment after 1 cycle of induction chemotherapy with 18F-FDG PET/CT and diffusion-weighted mri for response to radical chemoradiotherapy in head and neck squamous cell carcinoma. J Nucl Med. 2016;57(12):1843–1850.
   PubMed Web of Science ®Google Scholar
• Dirix P, Nuyts S. Evidence-based organ-sparing radiotherapy in head and neck cancer. Lancet Oncol. 2010;11(1):85–91.
   PubMed Web of Science ®Google Scholar
• Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66(4):981–991.
   PubMed Web of Science ®Google Scholar
• Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25(31):4873–4879.
   PubMed Web of Science ®Google Scholar
• Ghosh-Laskar S, Yathiraj PH, Dutta D, et al. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: long-term results. Head Neck. 2016;38(Suppl 1):E1481–E1487.
   PubMed Web of Science ®Google Scholar
• Marta GN, Silva V, De Andrade Carvalho H, et al. Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiother Oncol. 2014;110(1):9–15.
   PubMed Web of Science ®Google Scholar
• Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys. 2004;60(5):1425–1439.
   PubMed Web of Science ®Google Scholar
• Bartelink H, Van den Bogaert W, Horiot J-C, et al. Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial. Eur J Cancer. 2002;38:667–673.
   PubMed Web of Science ®Google Scholar
• Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99–02): an open-label phase 3 randomised trial. Lancet Oncol. 2012;13:145–153.
   PubMed Web of Science ®Google Scholar
• Driessen CML, Boer JPD, Gelderblom H, et al. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08–01): a randomized phase II study. Eur J Cancer. 2016;52:77–84.
   PubMed Web of Science ®Google Scholar
• Chen AM, Felix C, Wang P-C, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 2017;18(6):803–811.
   PubMed Web of Science ®Google Scholar
• Marur S, Li S, Cmelak AJ, et al. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx—ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2017 Feb 10;35(5):490-497.
   Web of Science ®Google Scholar
• Chera BS, Amdur RJ, Tepper J, et al. Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2015;93:976–985.
   PubMed Web of Science ®Google Scholar
• Barker JL Jr, Garden AS, Ang KK, et al. Quantification of volumetric and geometric changes occuring during fractionated radiotherapy for head and neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys. 2004;59:960–970.
   PubMed Web of Science ®Google Scholar
• Loo H, Fairfoul J, Chakrabarti A, et al. Tumor shrinkage and contour change during radiotherapy increase the dose to organ at risk but not the target volumes for head and neck cancer patients treated on the TomoTherapy HiArt™ system. Clin Oncol (R Coll Radiol). 2011;23:40–47.
   PubMed Web of Science ®Google Scholar
• Castadot P, Geets X, Lee JA, et al. Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemoradiation. Radiother Oncol. 2010;95:209–217.
   PubMed Web of Science ®Google Scholar
• Yang SN, Liao CY, Chen SW, et al. Clinical implications of the tumor volume reduction rate in head-and-neck cancer during definitive intensity-modulated radiotherapy for organ preservation. Int J Radiat Oncol Biol Phys. 2011;79:1096–1103.
   PubMed Web of Science ®Google Scholar
• Belli ML, Scalco E, Sanguineti G, et al. Early changes of parotid density and volume predict modifications at the end of therapy and intensity of acute xerostomia. Strahlenther Onkol. 2014;190(11):1001–1007.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Fiorentino A, Oliviero C, et al. Volumetric and dosimetric assessment by cone-beam computed tomography scans in head and neck radiation therapy: a monitoring in four phases of treatment. Technol Cancer Res Treat. 2014;13(4):325–335.
   PubMed Web of Science ®Google Scholar
• Hansen EK, Bucci MK, Quivey JM, et al. Repeat CT imaging and replanning during the course of IMRT for head and neck cancer. Int J Radiat Oncol Biol Phys. 2006;64:355–362.
   PubMed Web of Science ®Google Scholar
• Bhide SA, Davies M, Burke K, et al. Weekly volume and dosimetric changes during chemo-radiotherapy with intensity modulated radiation therapy for head and neck cancer: a prospective observational study. Int J Radiat Oncol Biol Phys. 2010;76:1360–1368.
   PubMed Web of Science ®Google Scholar
• Ricchetti F, Wu B, McNutt T, et al. Volumetric change of selected organs at risk during IMRT for oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2011;80:161–168.
   PubMed Web of Science ®Google Scholar
• Durante M, Loeffler JS. Charged particles in radiation oncology. Nat Rev Clin Oncol. 2010;7(1):37–43.
   PubMed Web of Science ®Google Scholar
• van de Water S, van Dam I, Schaart DR, et al. The price of robustness; impact of worst-case optimization on organ-at-risk dose and complication probability in intensity-modulated proton therapy for oropharyngeal cancer patients. Radiother Oncol. 2016;120(1):56–62.
   PubMed Web of Science ®Google Scholar
• Gunn GB, Blanchard P, Garden AS, et al. Clinical outcomes and patterns of disease recurrence after intensity modulated proton therapy for oropharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys. 2016;95:360–367.
   PubMed Web of Science ®Google Scholar
• Holliday EB, Garden AS, Rosenthal DI, et al. Proton therapy reduces treatment-related toxicities for patients with nasopharyngeal cancer: a case-match control study of intensity-modulated proton therapy and intensity-modulated photon therapy. Int J Particle Ther. 2015;2:19-28ù.
   Google Scholar
• Blanchard P, Frank SJ. Proton therapy for head and neck cancers. Cancer Radiother. 2017;21(6–7):515–520.
   PubMed Web of Science ®Google Scholar
• Kraan AC, van de Water S, Teguh DN, et al. Dose uncertainties in IMPT for oropharyngeal cancer in the presence of anatomical, range, and setup errors. Int J Radiat Oncol Biol Phys. 2013;87:888–896.
   PubMed Web of Science ®Google Scholar